Use the search to find what you are looking for
Dr Kai Keen Shiu is quoted in Medscape Wednesday, October 29, 2018 in an article entitled ‘Cancer of Unknown Primary: Finding Mutations Alters Therapy’ by Liam Davenport which begins:
‘More than two thirds of patients with cancer of unknown primary (CUP) have mutations detectable on circulating tumor DNA (ct-DNA) testing, or so-called liquid biopsy. For these patients, ct-DNA testing could alter their treatment and improve their outcomes, say UK researchers. The findings come from a proof of principle study presented here at the European Society for Medical Oncology (ESMO) 2018 Congress. The study included 25 patients with CUP. Main disease sites varied among the patients. Several patients had previously undergone testing with the Guardant360 (G360; Guardant Health) ct-DNA test, which assessed genetic variations across a panel of genes. The results showed that 68% of tumors were carrying mutations that were potentially treatable with targeted therapies……..
The full article: https://www.medscape.com/viewarticle/904072#vp_1